FRONTIER1: A Phase 1/2 Dose Escalation Study of a Novel Factor VIIIa Mimetic Bispecific Antibody, Mim8, for Evaluation of Safety, Pharmacokinetics and Efficacy FRONTIER1: A Phase 1/2 Dose Escalation Study of a Novel Factor VIIIa Mimetic Bispecific Antibody, Mim8, for Evaluation of Safety, Pharmacokinetics and Efficacy Haemin Go / Monday, July 11, 2022 0 962 Article rating: No rating Monday, July 11, 2022 July 11, 2022 | Pratima Chowdary, M.D., F.R.C.Path., Royal Free Hospital, London, United Kingdom Read more
Von Willebrand Factor–Targeting Thrombolysis to Overcome Tissue Plasminogen Activator Resistance In Vivo Von Willebrand Factor–Targeting Thrombolysis to Overcome Tissue Plasminogen Activator Resistance In Vivo Haemin Go / Monday, July 11, 2022 0 787 Article rating: No rating Monday, July 11, 2022 July 11, 2022 | Coen Maas, Ph.D., University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands Read more
Activation of the Plasma Contact System Triggers the Fat Embolism Syndrome Activation of the Plasma Contact System Triggers the Fat Embolism Syndrome Haemin Go / Monday, July 11, 2022 0 595 Article rating: No rating Monday, July 11, 2022 July 11, 2022 | Sandra Konrath, M.Sc., University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany Read more
Early Career Researchers Receive Editors' Awards Early Career Researchers Receive Editors' Awards Haemin Go / Monday, July 11, 2022 0 1802 Article rating: No rating Monday, July 11, 2022 Read more
Mim8 phase 1 & 2 data demonstrates potential as once monthly treatment for people with haemophilia A BryanAdminTest / Monday, July 11, 2022 0 318 Article rating: No rating Monday, July 11, 2022 Read more